These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Antiepileptic drugs to prevent neural degeneration associated with epilepsy: assessing the prospects for neuroprotection. Sutula T Epilepsy Res; 2002 Jun; 50(1-2):125-9. PubMed ID: 12151123 [No Abstract] [Full Text] [Related]
24. American Epilepsy Society - 57th Annual Meeting. Pitkänen A IDrugs; 2004 Feb; 7(2):125-7. PubMed ID: 15057654 [No Abstract] [Full Text] [Related]
25. Antiepileptogenic effects of glutathione against increased brain ADA in PTZ-induced epilepsy. Pence S; Erkutlu I; Kurtul N; Bosnak M; Alptekin M; Tan U Int J Neurosci; 2009; 119(5):616-29. PubMed ID: 19283589 [TBL] [Abstract][Full Text] [Related]
27. Recent trends in erythropoietin-mediated neuroprotection. McPherson RJ; Juul SE Int J Dev Neurosci; 2008 Feb; 26(1):103-11. PubMed ID: 17936539 [TBL] [Abstract][Full Text] [Related]
28. [Current developments in the therapy of epilepsy]. Scollo-Lavizzari G Schweiz Rundsch Med Prax; 1991 Jul; 80(27-28):737-8. PubMed ID: 1862264 [No Abstract] [Full Text] [Related]
29. Anticonvulsive prophylaxis of traumatic epilepsy in childhood. Minchev D Folia Med (Plovdiv); 1987; 29(4):7-12. PubMed ID: 3144508 [No Abstract] [Full Text] [Related]
31. Development of neuroprotective compounds in the pharmaceutical industry: where are we, and where are we going? Santilli N Prog Brain Res; 2002; 135():497-507. PubMed ID: 12143368 [No Abstract] [Full Text] [Related]
32. Review of the role of anticonvulsant prophylaxis following brain injury. Olson S J Clin Neurosci; 2004 Jan; 11(1):1-3. PubMed ID: 14642356 [TBL] [Abstract][Full Text] [Related]
33. Posttraumatic epilepsy: the challenge of translating discoveries in the laboratory to pathways to a cure. Dichter MA Epilepsia; 2009 Feb; 50 Suppl 2():41-5. PubMed ID: 19187293 [TBL] [Abstract][Full Text] [Related]
34. Can preventative antiepileptic therapy alter outcome in infants with tuberous sclerosis complex? Stafstrom CE; Holmes GL Epilepsia; 2007 Aug; 48(8):1632-4. PubMed ID: 17692053 [No Abstract] [Full Text] [Related]
35. Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases. Kucuk B; Cevik Y; Acar U; Sobaci G CNS Neurol Disord Drug Targets; 2015; 14(9):1225-34. PubMed ID: 26295821 [TBL] [Abstract][Full Text] [Related]
36. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Schmidt D Epileptic Disord; 2012 Jun; 14(2):105-13. PubMed ID: 22977896 [TBL] [Abstract][Full Text] [Related]
37. The many faces of erythropoietin: from erythropoiesis to a rational neuroprotective strategy--correspondence. Lapchak PA Expert Opin Investig Drugs; 2008 Oct; 17(10):1615-6. PubMed ID: 18808321 [No Abstract] [Full Text] [Related]
38. Protection of erythropoietin on experimental spinal cord injury by reducing the expression of thrombospondin-1 and transforming growth factor-beta. Fang XQ; Fang M; Fan SW; Gu CL Chin Med J (Engl); 2009 Jul; 122(14):1631-5. PubMed ID: 19719963 [TBL] [Abstract][Full Text] [Related]
39. Neurovascular protection by erythropoietin: from the bedside back to the bench. Tufekci KU; Genc K Stroke; 2010 Jul; 41(7):e462. PubMed ID: 20466988 [No Abstract] [Full Text] [Related]